XBIO - Xenetic inks clinical manufacturing contract with Catalent

• Xenetic Biosciences ( NASDAQ: XBIO ) said it engaged Catalent ( NYSE: CTLT ) to manufacture the company's recombinant protein Human DNase 1 for use in a cancer study.
• Catalent Pharma Solutions will carry out the cGMP manufacturing of DNase to help Xenetic advance to a phase 1 study, according to a July 7 press release.
• "We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin to support the advancement of Xenetic's DNase clinical development program and accelerating their path to first-in-human studies," said Vikalp Mohan, global vice president, head of Drug Substance at Catalent Biologics
• Xenetic said its interventional DNase based cancer platform is aimed at improving outcomes of existing treatments, including immunotherapies.

For further details see: